ICU Medical (NASDAQ:ICUI) Price Target Increased to $203.00 by Analysts at Raymond James

ICU Medical (NASDAQ:ICUI) had its target price hoisted by Raymond James from $185.00 to $203.00 in a research note released on Tuesday morning, The Fly reports. Raymond James currently has a positive rating on the medical instruments supplier’s stock.

Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered ICU Medical from a hold rating to a sell rating in a research report on Wednesday, August 14th. BidaskClub upgraded ICU Medical from a sell rating to a hold rating in a research report on Friday, October 25th. ValuEngine upgraded ICU Medical from a sell rating to a hold rating in a research report on Wednesday, October 2nd. Finally, TheStreet lowered ICU Medical from a b- rating to a c+ rating in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. ICU Medical presently has a consensus rating of Hold and an average target price of $242.00.

Shares of NASDAQ:ICUI traded down $0.28 on Tuesday, hitting $174.44. The company’s stock had a trading volume of 182,700 shares, compared to its average volume of 215,588. The company has a market capitalization of $3.62 billion, a PE ratio of 22.63 and a beta of 0.91. ICU Medical has a 1 year low of $148.89 and a 1 year high of $259.72. The company has a 50-day simple moving average of $160.20 and a 200 day simple moving average of $200.93.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Monday, November 11th. The medical instruments supplier reported $1.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.62 by $0.03. ICU Medical had a return on equity of 12.13% and a net margin of 5.66%. The firm had revenue of $307.47 million for the quarter, compared to analyst estimates of $297.83 million. During the same period last year, the company earned $1.85 EPS. The business’s quarterly revenue was down 6.0% compared to the same quarter last year. Sell-side analysts anticipate that ICU Medical will post 7.1 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other ICU Medical news, VP Virginia Ruth Sanzone sold 3,000 shares of ICU Medical stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $154.08, for a total transaction of $462,240.00. Following the completion of the transaction, the vice president now owns 55 shares in the company, valued at $8,474.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert S. Swinney sold 373 shares of ICU Medical stock in a transaction on Monday, October 14th. The shares were sold at an average price of $153.49, for a total value of $57,251.77. Following the transaction, the director now owns 18,845 shares of the company’s stock, valued at approximately $2,892,519.05. The disclosure for this sale can be found here. Insiders own 11.40% of the company’s stock.

A number of large investors have recently made changes to their positions in ICUI. Price T Rowe Associates Inc. MD raised its stake in shares of ICU Medical by 22.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,478,883 shares of the medical instruments supplier’s stock worth $876,365,000 after purchasing an additional 640,425 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of ICU Medical by 5.2% in the second quarter. Janus Henderson Group PLC now owns 2,825,836 shares of the medical instruments supplier’s stock worth $711,856,000 after purchasing an additional 140,123 shares during the last quarter. BlackRock Inc. raised its stake in shares of ICU Medical by 4.9% in the second quarter. BlackRock Inc. now owns 1,558,317 shares of the medical instruments supplier’s stock worth $392,555,000 after purchasing an additional 72,346 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of ICU Medical by 4.2% in the second quarter. JPMorgan Chase & Co. now owns 539,633 shares of the medical instruments supplier’s stock worth $133,867,000 after purchasing an additional 21,930 shares during the last quarter. Finally, Findlay Park Partners LLP raised its stake in shares of ICU Medical by 50.0% in the third quarter. Findlay Park Partners LLP now owns 450,000 shares of the medical instruments supplier’s stock worth $71,820,000 after purchasing an additional 150,000 shares during the last quarter. Institutional investors and hedge funds own 94.04% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Featured Story: Call Option

The Fly

Leave a Reply

Your email address will not be published. Required fields are marked *

*